Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
Key Highlights
- ➤APG-5918 R/R TCL study: ORR 44.7%, DCR 74.5%, with no dose-limiting toxicities
- ➤APG-5918 600 mg QD cohort: ORR 65.0% and DCR 95.0% in R/R TCL
- ➤Olverembatinib-lisaftoclax pediatric R/R Ph+ ALL: ORR 90.0%, all responders achieved CR
- ➤Olverembatinib-blinatumomab regimen: CR 84.6% and MRD negativity 83.3% in Ph+ BCP ALL/CML-LBP
- ➤Venetoclax R/R AML triplet: ORR 30% with AZA and median OS 4.73 months
Expert Statements
Yifan Zhai, Chief Medical Officer of Ascentage Pharma
“It’s particularly noteworthy that the selection of APG-5918 for an oral presentation comes with its first disclosure of clinical data. Meanwhile, olverembatinib and lisaftoclax have been featured at ASH for several consecutive years, with multiple combination therapy datasets being presented for the first time this year, highlighting their strong therapeutic potential. Our continuous presence at this premier international hematology conference reflects the recognition by the global hematology community of the scientific value and clinical potential of our investigational drug candidates. It also highlights our capability to sustain innovation and advance global clinical development. Looking ahead, Ascentage Pharma will continue to focus on hematologic malignancies and other therapeutic areas, further explore the therapeutic potential of our pipeline assets, and investigate novel combination regimens to bring forward additional innovative treatment options for patients around the world.”
ROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that multiple clinical and preclinical studies have been selected at the 68th American Society of Hematology (ASH) Annual Meeting, involving four of the Company’s proprietary innovative drug candidates, namely olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China, lisaftoclax (APG-2575), a potentially best-in-class Bcl-2 inhibitor approved in China, APG-5918, a PRC2/EED inhibitor, and APG-3288, a BTK protein degrader. These new data presentations highlight the Company's global innovation capabilities in hematologic malignancies. Notably, APG-5918 was selected for an oral presentation upon the first disclosure of its clinical data.
Get started
Create a free account to read the full story.